VITAMIN D IN INDIVIDUALS BEFORE ONSET OF RHEUMATOID ARTHRITIS – RELATION TO VITAMIN D BINDING PROTEIN AND ITS ASSOCIATED GENETIC VARIANTS

M. Brink, L. Johansson\(^1\), E. Nygren\(^1\), L. Arlested\(^1\), J. Hultdins\(^1\), S. Rantapää-Dahlqvist\(^1\). Public Health and Clinical Medicine, Rheumatology; \(^1\)Department of Medical Biosciences, Umeå University, Umeå, Sweden

**Background:** Vitamin D has been implicated as being involved in the aetiology of several autoimmune diseases including rheumatoid arthritis (RA). Previous studies present contradictory results. Vitamin D binding protein (DBP), the major transport protein, is also involved in various inflammatory processes.

**Objectives:** The aim of this study was to investigate the relationship between circulating levels of 25-hydroxyvitamin D (25(OH)D), DBP and polymorphisms in group-specific component (GC) in pre-symptomatic individuals and matched controls within prospective cohorts of the Northern Sweden.

**Methods:** Blood samples donated to the Medical Biobank prior to the onset of symptoms of RA (n=515, mean [SD] time before the onset of symptoms 6.2 [9.3] years) and from matched (2:1) population-based controls (n=267) were used. Plasma 25(OH) vitamin D levels were analysed using liquid chromatography tandem-mass spectrometry and DBP levels were analysed using enzyme-linked immunosorbent assay. GC polymorphisms (rs4588 and rs7041) were analysed with TaqMan assays (Applied Biosystems).

**Results:** Levels of 25(OH)D or DBP were not statistically different between pre-symptomatic individuals and controls in a crude, or a multiple-adjusted logistic regression model. However, an increased risk for future RA was found in females with DBP (OR 1.0001 [95%CI 1.00-1.0003]), adjusted for carriage of the major allele of rs4588, in a multiple-adjusted model (p<0.05).

**Conclusions:** This study indicated that vitamin D is not associated with the future risk of RA although increasing levels of DBP were however, associated with an increased risk of disease in females carrying the minor allele of a DBP encoding SNP.

**Acknowledgements:** Samples and data for the cohort were obtained through the Västerbotten Intervention Program, the Northern Sweden MONICA Study, and the marmmary screening program of Västerbotton. Staff of the Department of Biobank Research, Umeå University, aided in acquisition of samples and data.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.6494

**THU0121** MORTALITY RATE AND PREVALENCE OF CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS: 5-YEAR KARRA PROSPECTIVE STUDY

N. R. Kim, J.W. Kang, J.S. Eun, J.H. Kim, J.Y. Kang, J.S. Seo, G.B. Bae, S.J. Lee, E.J. Nam, Y.M. Kang. Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of Ireland

**Background:** Rheumatoid arthritis (RA), which is an autoimmune chronic arthritis, leads to elevated rates of disability and mortality. The main causes of mortality identified among RA patients are increased incidences of cardiovascular (CV) disease, which accounts for one-third to one-half of the premature deaths, infection and cancer.

In our previous study, we identified that cumulative inflammatory burden contributes to the development of carotid atherosclerosis through a synergistic interaction with conventional CV risk factors in patients with RA.

During the 2 years follow-up period, the mortality rate was 2.4% (10/412), and the main causes of death were infection (4/10) and CV disease (6/10).

**Objectives:** To investigate the incidences of mortality and CV disease in patients with RA in the 5 year Kyungpook National University Hospital Atherosclerosis Risk in Rheumatoid Arthritis (KARRA) prospective study.

**Results:** A total of 372 patients with RA and 162 healthy controls were followed up for 5 years or until deaths in a prospective KARRA cohort study (412 patients and 221 controls at baseline).

**Conclusions:** We analysed the incidence of CVD, conventional CV risk factors, RA disease activity and severity markers, medication histories, mortality rate, and causes of death.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.3548

**THU0122** IMAGING CHARACTERISATION OF REMISSION IN RHEUMATOID ARTHRITIS

N. Purkayastha\(^1\), W.S. Tan\(^1\), A. Mahto\(^1\), M. Lewis\(^1\), G. Lilo\(^1\), A. Nervani\(^1\), V. Rocher\(^1\), F. Humber\(^1\), C. Pitzalis\(^2\), S. Kelly\(^2\). Experimental Medicine and Rheumatology, William Harvey Research Institute; 2Rheumatology, Bart’s Health NHS Trust, London, UK

**Background:** Remission in rheumatoid arthritis (RA) is now achievable in a significant proportion of patients using a combination of a treat to target strategy and biologic therapy. A number of clinical assessment tools exist for assessing remission. Several reports have shown that ultrasound (US) may have a role in better characterising this group of patients suggesting that subclinical synovitis increases the risk of erosive disease and flares in patients in DAS28 remission.

**Objectives:** To develop a imaging tool to assess remission in rheumatoid arthritis (RA).

**Methods:** We performed an observational study of 100 consecutive patients in DAS28 remission. All patients underwent a standardised ultrasound examination of four target sites (index; RF; rheumatoid factor. A positive estimate reflects a higher DAS28 over time, corrected for baseline DAS28, and thus a lesser effect of the concomitant prednisone therapy.

**Conclusions:** To our knowledge, this is the first time that smoking is shown to be a negative predictor for clinical response to pred in RA patients. Cessation of smoking needs to be encouraged in patients initiating bDMARDs, MTX and pred and in those already on these drugs.

**References:**


**Disclosure of Interest:** None declared

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.6738